Sucampo Pharmaceuticals (Sucampo Pharmaceuticals) Total Liabilities : $348.5 Mil (As of Sep. 2017)

View and export this data going back to 2007. Start your Free Trial

What is Sucampo Pharmaceuticals Total Liabilities?

Sucampo Pharmaceuticals's Total Liabilities for the quarter that ended in Sep. 2017 was $348.5 Mil.

Sucampo Pharmaceuticals's quarterly Total Liabilities declined from Mar. 2017 ($354.90 Mil) to Jun. 2017 ($338.74 Mil) but then increased from Jun. 2017 ($338.74 Mil) to Sep. 2017 ($348.51 Mil).

Sucampo Pharmaceuticals's annual Total Liabilities increased from Dec. 2014 ($59.26 Mil) to Dec. 2015 ($370.73 Mil) but then declined from Dec. 2015 ($370.73 Mil) to Dec. 2016 ($353.75 Mil).

Sucampo Pharmaceuticals Total Liabilities Historical Data

The historical data trend for Sucampo Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sucampo Pharmaceuticals Total Liabilities Chart

Sucampo Pharmaceuticals Annual Data

Trend

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Total Liabilities

Get a 7-Day Free Trial

84.77

77.91

59.26

370.73

353.75

Sucampo Pharmaceuticals Quarterly Data
	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17
Total Liabilities	Get a 7-Day Free Trial															314.75	353.75	354.90	338.74	348.51

Sucampo Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Sucampo Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2016 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	32.351	+	(290.516	+	8.791
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	22.094	+	0)
	=	353.8

Total Liabilities	=	Total Assets (A: Dec. 2016 )	-	Total Equity (A: Dec. 2016 )
	=	520.851	-	167.099
	=	353.8

Sucampo Pharmaceuticals's Total Liabilities for the quarter that ended in Sep. 2017 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	37.178	+	(293.539	+	5.615
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	12.178	+	0)
	=	348.5

Total Liabilities	=	Total Assets (Q: Sep. 2017 )	-	Total Equity (Q: Sep. 2017 )
	=	388.144	-	39.634
	=	348.5

Sucampo Pharmaceuticals Total Liabilities Related Terms

Thank you for viewing the detailed overview of Sucampo Pharmaceuticals's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Sucampo Pharmaceuticals (Sucampo Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sucampo Pharmaceuticals Inc (NAS:SCMP) » Definitions » Total Liabilities

Traded in Other Exchanges

N/A

Address

Website

http://www.sucampo.com

Sucampo Pharmaceuticals Inc is a part of the healthcare sector in the United States. As a global pharmaceutical company, it commercializes drugs for the treatment of various gastrointestinal, ophthalmic and oncology-based inflammatory disorders. It currently generates revenue mainly from product royalties, product sales, upfront and milestone payments, and reimbursements for development activities.

Executives

Peter Greenleaf	officer: Chief Executive Officer	ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Maureen Oconnell	director
Karen L. Smith	director	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Jones W. Bryan	officer: Sr. Vice Pres., BD & Licensing	C/O SUPERNUS PHARMACEUTICALS, INC., 1550 EAST GUDE DRIVE, ROCKVILLE MD 20850
Robert J. Spiegel	director	C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Timothy P Walbert	director	1033 SKOKIE BOULEVARD, SUITE 355, NORTHBROOK IL 60062
Peter A Kiener	officer: Chief Science Officer	40 GUEST STREET, BOSTON MA 02135
John Johnson	director	DENDREON CORPORATION, 1301 2ND AVENUE, SEATTLE WA 98101
Peter P. Pfreundschuh	officer: CFO	C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Paul R Edick	director	C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AMES IA 50010
Thomas J Knapp	other: Former Officer	4640 SW MACADAM AVE., SUITE 270, PORTLAND OR 97239
William Ashton	director	C/O HARRISON CONSULTING GROUP, PO BOX 283, NEWTOWN SQUARE PA 19073
Timothy I Maudlin	director	18739 VOGEL FARM TRAIL, EDEN PRAIRIE MN 55347
Nantahala Capital Management, Llc	10 percent owner	130 MAIN ST., 2ND FLOOR, NEW CANAAN CT 06840
Mariam E Morris	officer: Chief Acctg. Officer, Treas.	C/O SUCAMPO PHARMACEUTICALS, 4520 EAST-WEST HIGHWAY, SUITE 300, BETHESDA MD 20814